

# Nicole Skoetz

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9452725/nicole-skoetz-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104  
papers

4,524  
citations

28  
h-index

66  
g-index

125  
ext. papers

6,132  
ext. citations

5.9  
avg, IF

5.27  
L-index

#	Paper	IF	Citations
104	Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. <i>BMJ, The</i> , <b>2020</b> , 369, m1328	5.9	1283
103	Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>The Cochrane Library</i> , <b>2011</b> , CD008794	5.2	353
102	Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 706-14	9.7	299
101	Living systematic review: 1. Introduction-the why, what, when, and how. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 23-30	5.7	211
100	GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 119, 126-135	5.7	174
99	Living systematic reviews: 2. Combining human and machine effort. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 31-37	5.7	156
98	Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 914-8	5.1	155
97	Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin lymphoma: a systematic review and network meta-analysis. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 943-52	21.7	132
96	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet, The</i> , <b>2015</b> , 385, 1418-27	40	116
95	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2020</b> , 7, CD013600	5.2	100
94	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. <i>The Cochrane Library</i> , <b>2020</b> , 5, CD013600	5.2	85
93	Living systematic reviews: 4. Living guideline recommendations. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 47-53	5.7	81
92	Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	78
91	High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	78
90	Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. <i>Haematologica</i> , <b>2010</b> , 95, 494-500	6.6	77
89	Living systematic reviews: 3. Statistical methods for updating meta-analyses. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 38-46	5.7	74
88	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2020</b> , 10, CD013600	5.2	64

87	Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 179-88	7	51
86	Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. <i>The Cochrane Library</i> , <b>2014</b> , CD010189	5.2	50
85	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin lymphoma. <i>The Cochrane Library</i> , <b>2007</b> , CD003805	5.2	48
84	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2021</b> , 5, CD013600	5.2	45
83	High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. <i>The Cochrane Library</i> , <b>2013</b> , CD009411	5.2	39
82	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , <b>2021</b> , 9, CD013825	5.2	39
81	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , <b>2021</b> , 7, CD015017	5.2	36
80	Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. <i>The Cochrane Library</i> , <b>2017</b> , 5, CD007941	5.2	35
79	Vitamin D supplementation for the treatment of COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2021</b> , 5, CD015043	5.2	35
78	Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 88, 178-86	7	28
77	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. <i>Cochrane Database of Systematic Reviews</i> , <b>2011</b> , CD007110		28
76	Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. <i>Cochrane Database of Systematic Reviews</i> , <b>2011</b> , CD007941		26
75	Adverse effects of biologics: a network meta-analysis and Cochrane overview <b>2010</b> ,		26
74	High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 92, 1-10	7	25
73	Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. <i>The Cochrane Library</i> , <b>2012</b> , 11, CD008079	5.2	25
72	GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 118, 124-131	5.7	25
71	Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 85, 21-31	7	24
70	Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. <i>The Cochrane Library</i> , <b>2012</b> , CD009159	5.2	23

69	Alemtuzumab for patients with chronic lymphocytic leukaemia. <i>The Cochrane Library</i> , <b>2012</b> , CD008078	5.2	21
68	Systemic corticosteroids for the treatment of COVID-19. <i>The Cochrane Library</i> , <b>2021</b> , 8, CD014963	5.2	21
67	Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1159-70	9.7	17
66	Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. <i>The Cochrane Library</i> , <b>2015</b> , 1, CD010533	5.2	15
65	Yoga in addition to standard care for patients with haematological malignancies. <i>The Cochrane Library</i> , <b>2014</b> , CD010146	5.2	15
64	High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. <i>The Cochrane Library</i> , <b>2012</b> , 1, CD007678	5.2	15
63	Hodgkin Lymphoma in Adults. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2018</b> , 115, 535-540	2.5	15
62	Hodgkin lymphoma in adults: diagnosis, treatment and follow-up. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2013</b> , 110, 177-83, 183e1-3	2.5	14
61	Developing trustworthy recommendations as part of an urgent response (1-2 weeks): a GRADE concept paper. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 129, 1-11	5.7	14
60	Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). <i>The Cochrane Library</i> , <b>2012</b> , 11, CD009355	5.2	13
59	Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. <i>The Cochrane Library</i> , <b>2015</b> , CD010615	5.2	10
58	The role of additional radiotherapy for primary central nervous system lymphoma. <i>The Cochrane Library</i> , <b>2014</b> , CD009211	5.2	10
57	Antibiotics for the treatment of COVID-19. <i>The Cochrane Library</i> , <b>2021</b> , 10, CD015025	5.2	10
56	Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. <i>The Cochrane Library</i> , <b>2020</b> , 7, CD012022	5.2	10
55	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. <i>The Cochrane Library</i> , <b>2013</b> , CD008908	5.2	9
54	Colchicine for the treatment of COVID-19. <i>The Cochrane Library</i> , <b>2021</b> , 10, CD015045	5.2	9
53	Gender differences in health literacy of migrants: a synthesis of qualitative evidence. <i>The Cochrane Library</i> ,	5.2	9
52	Nivolumab for adults with Hodgkin lymphoma (a rapid review using the software RobotReviewer). <i>The Cochrane Library</i> , <b>2018</b> , 7, CD012556	5.2	8

51	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. <i>The Cochrane Library</i> , <b>2020</b> , 12, CD013020	5.2	8
50	Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. <i>The Cochrane Library</i> , <b>2017</b> , 4, CD007110	5.2	7
49	The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin lymphoma. <i>Deutsches Arzteblatt International</i> , <b>2012</b> , 109, 893-9	2.5	7
48	A Systematic Review on Predictors of Working Memory Training Responsiveness in Healthy Older Adults: Methodological Challenges and Future Directions. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 575804	5.3	7
47	Prognostic factors for change in memory test performance after memory training in healthy older adults: a systematic review and outline of statistical challenges. <i>Diagnostic and Prognostic Research</i> , <b>2020</b> , 4, 7	5.5	6
46	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. <i>The Cochrane Library</i> , <b>2020</b> , 1, CD012643	5.2	6
45	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. <i>Cochrane Database of Systematic Reviews</i> , <b>2012</b> , 1, CD008908		6
44	European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	6
43	Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. <i>The Cochrane Library</i> , <b>2021</b> , 11, CD012775	5.2	6
42	Interventions for improving health literacy in migrants. <i>The Cochrane Library</i> , <b>2019</b> ,	5.2	6
41	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). <i>Infection</i> , <b>2021</b> , 1	5.8	6
40	A consumer network for haematological malignancies. <i>Health Expectations</i> , <b>2005</b> , 8, 86-90	3.7	5
39	Recommendations on the In-Hospital Treatment of Patients With COVID-19. <i>Deutsches Arzteblatt International</i> , <b>2021</b> ,	2.5	5
38	Mindfulness-based interventions for substance use disorders. <i>The Cochrane Library</i> , <b>2021</b> , 10, CD011723	5.2	5
37	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. <i>The Cochrane Library</i> , <b>2019</b> , 2019,	5.2	5
36	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , <b>2022</b> , 2022,	5.2	5
35	Gender-Specific Aspects of Health Literacy: Perceptions of Interactions with Migrants among Health Care Providers in Germany. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	4
34	Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, NP	9.7	4

33	GRADE concept paper 2: Concepts for Judging Certainty on the Calibration of Prognostic Models in a Body of Validation Studies. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> ,	5.7	4
32	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. <i>The Cochrane Library</i> , <b>2019</b> , 9, CD012643	5.2	4
31	Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer). <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	3
30	Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, E1	9.7	3
29	Therapeutic interventions for Burkitt lymphoma in children. <i>The Cochrane Library</i> , <b>2011</b> , CD005198	5.2	3
28	Thirteenth biannual report of the Cochrane Haematological Malignancies Group--focus on multiple myeloma. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, E1-19	9.7	3
27	Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care. <i>BJU International</i> , <b>2021</b> ,	5.6	3
26	Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. <i>Journal of Clinical Epidemiology</i> , <b>2019</b> , 108, 1-9	5.7	3
25	Inhaled corticosteroids for the treatment of COVID-19.. <i>The Cochrane Library</i> , <b>2022</b> , 3, CD015125	5.2	3
24	Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	2
23	Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	2
22	Yoga for haematological malignancies <b>2012</b> ,		2
21	High-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patients <b>2011</b> ,		2
20	"The system has to be health literate, too" - perspectives among healthcare professionals on health literacy in transcultural treatment settings. <i>BMC Health Services Research</i> , <b>2021</b> , 21, 716	2.9	2
19	Interventions for palliative symptom control in COVID-19 patients. <i>The Cochrane Library</i> , <b>2021</b> , 8, CD015061	5.6	2
18	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , <b>2021</b> , 9, CD013365	5.2	2
17	Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patients <b>2013</b> ,		1
16	Alemtuzumab for chronic lymphocytic leukaemia <b>2009</b> ,		1

15	Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia <b>2009</b> ,		1
14	Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, E1	9.7	1
13	Clinical Practice Guideline: Follicular Lymphoma Diagnosis, Treatment, and Follow-up. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2021</b> , 118,	2.5	1
12	Prognostic Models for Changes in Memory Performance After Memory Training in Healthy Older Adults: a Systematic Review. <i>Journal of Cognitive Enhancement: Towards the Integration of Theory and Practice</i> , <b>2021</b> , 5, 372-385	2.4	1
11	Methods and guidance on conducting, reporting, publishing and appraising living systematic reviews: a scoping review protocol.. <i>F1000Research</i> , <b>2021</b> , 10, 802	3.6	1
10	Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 141, 82-89	5.7	1
9	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.. <i>Lancet Haematology</i> , <b>2022</b> , 9, e361-e373	14.6	1
8	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , <b>2022</b> ,	5.2	1
7	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. <i>Journal of Evidence-Based Medicine</i> , <b>2011</b> , 4, 142-143	6.1	0
6	Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol. <i>F1000Research</i> , <b>2021</b> , 11, 109	3.6	0
5	GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes-Study limitations due to censoring of participants with missing data in intervention studies. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 129, 126-137	5.7	0
4	BEACOPP or no BEACOPP? - authors Reply. <i>Lancet Oncology</i> , <b>2013</b> , 14, e488-9	21.7	
3	Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, E1	9.7	
2	Third biannual report of the Cochrane Haematological Malignancies Group. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, E2	9.7	
1	Evidence on the efficacy of ivermectin for COVID-19: another story of apples and oranges. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> ,	2.7	